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Benzoyl peroxide (BPO) is used extensively for the treatment of acne but is known to 
induce concentration-related skin irritation. We postulate that this side effect may be 
prevented by using BPO encapsulated in liposomes. The objectives of this study were to 
develop, optimize and characterize liposomal preparations of BPO to determine its 
antibacterial efficacy and storage stability.  
 
BPO-loaded liposomes having mean size ranging from 250 to 900 nm were successfully 
prepared using a combination of cholesterol and phosphatidylcholine. Sonication was 
necessary to obtain the smaller sized liposomes. The residual BPO content in the 
liposomes was dependent on the pressures applied during the drying down and hydration 
of lipids. Applying a low pressure during drying down led to a rapid evaporation of the 
organic solvent, and resulted in a substantial drug loss. Processes involved in extracting 
the drug from the liposomes for the determination of drug loading, e.g. method and 
duration of agitation, and method of filtration, did not affect the BPO content in the 
liposomes. BPO-loaded liposomes prepared with operating pressures of 450 atm during 
solvent evaporation and 150 atm during lipid hydration yielded a high encapsulation 
efficiency of >90%. Sustained release of the encapsulated BPO was obtained upon 
dilution with an aqueous medium at pH 7.4, with less than 40% of the drug load released 
in 24 h. Smaller liposomes of 350 nm, prepared by prolonging the duration of sonication, 
were found to have slower rates of drug release due to their propensity to form 
aggregates.  
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Liposomes containing BPO concentrations ranging from 12.5 to 100.0 mg/ml were 
prepared for the study of its antibacterial activity against P. acnes. Upon storage for 3 
weeks at 4°C, the mean size of the liposomes increased from 800 nm to more than 2000 
nm while those stored for 3 weeks at room temperature decreased in size from 800  nm to  
400 nm or less. To obtain more stable liposomes, the phosphatidylcholine:cholesterol 
mole ratio was increased from 3:1 to 1:1. These liposomes showed much smaller changes 
in mean size upon storage. However, the BPO encapsulation efficiency was reduced from 
74 - 83% to 60 - 65% after 3 weeks of storage at 4°C and room temperature. This 
reduction was due to the diffusion of BPO out of the liposomes over time, as evident 
from the results of the in vitro drug release studies, in which only about 50% of the BPO 
was released after 24 h.  
 
The antibacterial efficacy of the BPO-loaded liposomes, determined by measuring the 
zone of inhibition produced against P. acnes, was not affected by the increase in the 
cholesterol content of the liposomes. However, the antibacterial efficacy of the liposomes 
was increased after storage, as evident from the bigger zones of inhibition produced by 
liposomes stored for 3 weeks at either 4°C or room temperature. In contrast, the control 
BPO solutions produced comparable zones of inhibition before and after storage. From 
these results, it is clear that BPO retained its antibacterial activity against P. acnes when 
encapsulated in liposomes.  
 
Key Words: Nano-liposomes; Acne Treatment; Benzoyl Peroxide; Topical Drug 
Delivery; Antibacterial Activity 
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Acne is an inflammatory disease of the sebaceous glands which induces inflammation at 
the skin surface of the face, neck, chest and back. Most people would not be affected by 
small, non-inflamed acne lesions, but in individuals with very severe inflammatory 
nodular acne, they can suffer from social embarrassment, trauma, pain and both physical 
and psychological scarring. Acne develops mostly in young people due to several factors, 
namely, hormonal imbalances (overproduction of the male sex hormones), heredity or 
genetics, consumption of certain drugs (including androgens, lithium, and barbiturates) 
and food, exposure to environmental irritants (such as pollution and high humidity), 
stress, cosmetic application, bacterial infection, squeezing or picking at blemishes, and 
hard scrubbing of the skin (Ghyczl et al., 1996).  
 
Scientists have made tremendous progress over the last twenty-five years in their research 
of the pathogenesis of acne, and improved treatment alternatives have caused the lives of 
many patients to change for the better. Drugs currently used for the treatment of acne 
include benzoyl peroxide, antibiotics, retinoids and oral contraceptives. Procedure-
oriented acne treatments involve the exposure of lesions to light (photodynamic 
treatment) and laser. The four key contributing factors of acne are follicular epithelial 
hyperproliferation and resultant follicular plugging, excess sebum, inflammation and the 
presence and activity of Propionibacterium acnes (P. acnes). 
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Acne can comprise of non-inflammatory and inflammatory lesions. The initial non-
inflammtory lesion can be verified by light or electron microscopy (Toyoda and 
Morohashi, 2001). The lesion results in micro-comedo, which then leads to closed or 
open comedone. Inflammatory lesions begin to form when the proliferation of P. acnes 
causes the secretion of leukocyte chemotatic factors, which progresses to the infiltration 
of leukocytes into the hair follicle. Thereafter, the contents of the hair follicle flow into 
the dermis to initiate inflammation (Webster et al., 1980). In most cases, the 
inflammation gradually fades after a few days to 2 weeks. Most acne patients regain 
complete recovery without any remaining symptoms, while a minority of patients suffers 
from prolonged acne or other consequences, like scarring and keloid formation. 
 
1.2 The role of P. acnes 
P. acnes is a major inhabitant of adult human skin (Marples, 1974), and high population 
densities are associated with skin sites possessing high numbers of sebum secreting 
sebaceous follicles (McGinley et al., 1978). However, the degree of inflammation seen in 
acne vulgaris is dependent upon an individual’s immune response to P. acnes. (Thiboutot 
et al., 1999). P. acnes causes an inflammation in the sebaceous glands or hair pores when 
it secretes lipase and degrades sebum oils into free fatty acids, both of which are potent 
stimuli (Webster et al., 1978). These free fatty acids stimulate the hair follicle, form the 
comedo, and then induce the inflammation which leads to the formation of papules and 
pustules (Downing et al., 1986).  
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The three important physiological factors in the pathogenesis of acne are the 
multiplication of P. acnes, the overproduction of sebum and follicular 
hyperkeratinization. It is widely known that the action of P. acnes lipase on sebaceous 
triglycerides results in the free fatty acids detected in acne lesions. Marples et al. (1974) 
reported that a decrease in free fatty acids precedes a decline in the numbers of P. acnes. 
Free fatty acids stimulate the follicular epithelium sufficiently to result in its breakdown, 
which then enables the free fatty acids to penetrate the dermis and induce inflammation. 
Intradermal injection of free fatty acids into healthy subjects induces serious 
inflammation (Strauss et al., 1965). Therefore, P. acnes is considered to play an 
important role in acne development by secreting inflammation-inducing factors. 
 
1.3 Treatment of acne 
The past 25 years have brought about significant changes in the treatment of acne. 
Topical retinoids, which are anti-inflammatory and comedolytic, became the mainstream 
acne treatment in the early 1980s, but problems with skin irritation limited their use in 
some individuals.  Adapalene, a topical retinoid by function, was introduced in the mid 
1990s, followed quickly by formulations of tretinoin and tazarotene, which were less 
irritating, yet more effective in the treatment of acne. Topical retinoids, either alone or in 
combination with other acne medications (e.g. tretinoin and oral antibiotics), have since 
been promoted as an effective treatment for inflammatory acne. They are also 




Antibiotics continue to be an important therapeutic option in the management of acne 
despite evidence of bacterial resistance. Tetracycline used to be the mainstay of acne 
treatment, but is largely replaced by doxycycline and minocycline as first-line anti-acne 
antibiotics, due to increasing P. acnes resistance. More recently, low-dose doxycycline 
(doses below 2.5% w/v), which does not alter the microbial colony counts in acne 
patients, has been shown to be effective in the treatment of acne. The low dose of 
antibiotic, despite a failure to reduce microbial colony counts, is postulated to exhibit 
anti-inflammatory properties that lower the biological activity of P. acnes and render the 
bacteria less capable of inciting further inflammation (Skidmore et al., 2003). That said, 
the long-term use of antibiotics for acne treatment continues to raise concerns regarding 
the development of colonization with potential pathogens and bacterial resistance.  
 
Oral contraceptive is another accepted therapeutic modality for the treatment of acne in 
women. All combination oral contraceptive pills have the potential to improve acne, and 
they work by increasing the sex hormone-binding globulin and decreasing the circulating 
free testosterone. (Van Vloten et al., 2002).  
 
Procedure-oriented acne treatments, which include light, laser and photodynamic 
treatments, are introduced at an increasing frequency. Blue and red light, which may 
improve acne in some individuals (Kawada et al., 2002), target different pathogenetic 
factors. Blue light (405-420 nm) reacts with porphyrins produced by P. acnes to create 
reactive oxygen species that damage the bacterial cell wall and cause bacterial death 
(Kawada et al., 2002). Red light (660 nm) is anti-inflammatory (Cornelius et al., 1967). 
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The efficacy and safety of light therapy for acne remain to be established, given the 
paucity of clinical trials, none of which offers long-term follow-up (Ruis-Esparza et al., 
2003). Similarly, there is a lack of controlled clinical trials on photodynamic therapy 
(PDT) which utilizes blue light to cause a porphyrin reaction that leads to the damage and 
destruction of the sebaceous gland (Mills et al., 1978). The efficacy of laser treatment, 
which is postulated to cause sebaceous gland damage and destruction in individuals with 
acne vulgaris (Walia and Alster., 1999), has also yet to be proven in controlled trials.  
 
Benzoyl peroxide (BPO) (C14H10O4) is an antimicrobial agent with weak comedolytic 
properties (Barry, 1998). It is commonly applied as a topical formulation for the treatment 
of acne, and has been shown to be bactericidal against P. acnes (Leyden et al., 1980) at a 
MIC of 2.5% w/v. Topical treatment with BPO causes a decrease in P. acnes count. 
(Cove et al., 1980). In addition, an inhibition of sebaceous gland secretion (Gloor et al., 
1980) and a change of epidermopoiesis (Mezick et al., 1980) have been reported.  
 
The oxidizing nature of BPO is important for both its pharmacological effects and 
undesired properties. BPO can form highly reactive radicals in which two benzoate 
molecules are interlinked to give a relatively unstable O-O bond that has a bond energy of 
approximately 30 kcal/mol, as compared to 83 kcal/mol for the C-C bond (Chellquist and 
Gorman, 1992). Upon thermal degradation, even at temperatures < 40ºC, BPO forms 
benzoate radicals, which may in turn react with multiple targets. The stability of BPO in 
pharmaceutical formulations depends in part on the solvents employed. Bollinger et al. 
(1977) found that gel formulations containing 10% BPO were less stable when prepared 
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with 40% v/v alcohol (40% loss) than with 5% v/v propylene glycol (10% v/v loss) and 
10% v/v chloroform (no measurable loss).  
 
BPO continues to be a widely used acne treatment option even with the development of 
newer and better comedolytic agents, antibiotics and antimicrobials. While P. acnes has 
developed a considerable amount of resistance to erythromycin and tetracycline, BPO is 
able to effectively eradicate this acne-associated bacteria (Fluhr, 1999). In addition, 
bacterial resistance to BPO has not been reported. Furthermore, combination of BPO with 
topical or systemic antibiotics may decrease the development of resistance to the co-
administered antibiotic (Harper, 2004). 
 
BPO formulations are available as lotions, creams, gels and solutions, at concentrations 
of 2.5, 5 or 10% w/w (Billow, 1986). These formulations may contain water, propylene 
glycol, isopropyl myristate, acetone, or alcohol as vehicle, and are often associated with 
side effects that include erythema, itching, burning, scaling and irritation 
(http://www.nih.gov/medlineplus/druginfo/uspdi/202086.htm, 2003). The side effects are 
believed to be caused by the degreasing and keratolytic properties of BPO, which can 
lead to xerosis or excessive drying of the skin upon long term use. The keratolytic 
properties stem from the BPO metabolite, benzoic acid, which lyses intercellular 
substance in the stratum corneum. It has been postulated that the side effects of BPO can 
be circumvented by formulating BPO into nano-sized liposomes (Allen, 1998). A 
liposome formulation may also have the added advantage of giving a controlled release of 
BPO with time (Maurer et al., 2001). 
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 1.4 Liposomes 
Table 1. Description of liposomes according to particle size 
 
Type of vesicle Term used Approximate size (nm) 
Small Unilamellar  SUV 15-30 
Large Unilamellar LUV 100-200 
Multilamellar  MLV > 200 
 
Liposomes are colloidal particles in which phospholipid bilayers encapsulate part of the 
medium into their interior. They are formed spontaneously by the self-assembly of 
phospholipid molecules in an aqueous medium. Liposomes can be classified according to 
their size distribution (Table 1). A single lipid bilayer enclosing an aqueous compartment 
is referred to as a unilamellar lipid vesicle and, according to size, is known as small 
unilamellar vesicle (SUV) or large unilamellar vesicle (LUV). If multiple bilayers are 
present, the vesicle is known as a multilamellar vesicle (MLV).  
 
Depending on the lipid composition, methods of preparation and the nature of the 
encapsulate agents, many types of liposomal products can be formulated. The lipids most 
commonly used to prepare liposomes are phosphatidic acid (PA), phosphatidylserine 
(PS), phosphatidylethanolamine (PE), phosphatidylcholine (PC), phosphatidylglycerol 
(PG), phosphatidylinositol (PI), and cholesterol (CH). Glycerol-containing phospholipids 
are by far the most commonly used component of liposomal formulations, probably 
because they represent more than 50% of the weight of lipids present in biological 
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membranes (Lasic, 1993). The most abundant glycerol phosphatides in plants and 
animals are PC, also called lecithin, and PE, sometimes referred to as cephalin (Janoff, 
1998). These two phosphatides constitute the major structural components of most 
biological membranes. In PS, the phosphoric acid moiety of PA is esterified to the 
hydroxyl group of the amino acid L-serine, and in PI to one of the hydroxyls of the cyclic 
sugar alcohol inositol. In the case of PG, the alcohol that is esterified to the phosphate 
moiety is glycerol. Saturated phospholipids, including disteroylphosphatidylcholine 
(DSPC), dipalmitoylphosphatidylethanolamine (DPPE), dipalmitoylphosphatidylcholine 
(DPPC), dipalmitoylphosphatidic acid (DPPA), dipalmitoylphosphatidylserine (DPPS), 
and dipalmitoylphosphatidylglycerol (DPPG), and several unsaturated phospholipids, 
such as dioleoylphosphatidylglycerol (DOPG) and dioleoylphosphatidylcholine (DOPC) 
are also commonly used in liposomal formulations. 
 
Unlike phospholipids, sphingolipids contain sphingosine or a related base as their 
structural backbone. Sphingomyelin is the most abundant sphingolipid in higher animals 
(Lasic, 1993), which contains either phosphorylcholine or phosphorylethanolamine 
esterified at the 1-hydroxy group of ceramide as its polar head group. As for their 
physical properties, sphingomyelins behave quite similarly to phospholipids in that they 
are zwitterions at pH 7, and they readily form bilayer structures in aqueous media 
(Marsh, 1990). A second class of sphingolipids, known as gangliosides, are found mainly 
in the gray matter of brain tissue of higher animals. They provide surface-charged groups 
when used as a minor component of some liposome formulations (Marsh, 1990).  
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Liposomal membranes often include cholesterol (CH) and its derivatives as components. 
CH is found in large quantities in animal tissues and is concentrated in cell membranes. 
Its inclusion in liposomal membranes has three recognized effects: 1) decreasing the 
fluidity or microviscosity of the bilayer (Berestein and Fuller., 1989); 2) reducing the 
permeability of the membrane to water-soluble molecules (Ostro, 1987); and 3) 
stabilizing the membrane in the presence of biological fluids such as plasma (Berestein 
and Fuller, 1989). This latter effect has proven useful in formulating liposomes for drug 
delivery applications that use the intravenous route of administration. 
 
The most important point in the manufacture of liposomes for pharmaceutical 
applications is that the lipid membrane form spontaneously due to its interactions with 
water. Therefore, the focus in making liposomes is to get the membrane to form vesicle 
with the right size and structure, so as to entrap materials with high efficiency in order 
that the materials will not leak out of the formed liposomes. There are 4 basic stages 
involved in making liposomes: drying down of lipids from organic solvents, dispersion of 
lipids in aqueous media, purification of the resultant liposomes, and analysis of the final 
product (Armann et al., 1990). The only difference amongst the numerous methods of 
liposome manufacture is in the way in which the membrane components are dispersed in 
aqueous media, before being allowed to coalesce in the form of bilayer sheets. The 
methods can be categorized to three basic modes of dispersion and they are the physical 
dispersion, two-phase dispersion, and detergent solubilization (Hamilton et al., 1984). 
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In the physical dispersion group of methods, the lipids are first dried down onto a solid 
support, and the aqueous medium is added to aid dispersion before the liposomes are 
finally formed by shaking. Before its exposure to water, the lipids in the dried down film 
are oriented such that the hydrophobic and hydrophilic regions are separated from each 
other, just like their confirmation in the finished membrane preparation. After hydration, 
the lipids ‘swell’, and peel off the support in sheets, to form multilamellar vesicles.  
 
With the second category known as the two-phase or solvent dispersion methods, the 
aqueous phase containing the material to be encapsulated within the liposome is brought 
into contact with the lipids dissolved in an organic solution. At the interface between the 
aqueous and organic phases, the phospholipids align themselves into a monolayer to form 
half of the bilayer of the liposome. Methods employing solvent dispersion fall into one of 
these three categories: 1) those in which the organic solvent is miscible with the aqueous 
phase; 2) those in which the organic solvent is immiscible with the aqueous phase, the 
latter being in a large excess; and 3) those in which the organic solvent is in large excess, 
and is again immiscible with the aqueous phase. 
 
Finally, in the detergent solubilization class of methods, detergents are used as an 
intermediary to bring the lipids into close contact with the aqueous phase. The detergent 
associates with the lipid molecules and functions to screen the hydrophobic portions of 
the molecules from water. Micelles which form from this association are composed of 
several hundred component molecules, their shape and size depending on the 
involvement of other lipids and the chemical nature of the detergent. After the detergent 
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is subsequently removed from the mixed micelles containing the lipids, unilamellar 
liposome vesicles then form spontaneously. 
 
Most drugs can be encapsulated into liposomes due to their biphasic nature (lipid and 
water). Where the drug finally resides depends on its solubility in the liposome 
components. Hydrophobic materials will reside in the lipid bilayers and hydrophilic 
materials in the aqueous compartments. In order to stabilize the liposomal membrane and 
to minimize the leaching out of an encapsulated water-soluble drug, cholesterol is usually 
included in the formula. In addition, the incorporation of cholesterol into liposomal 
bilayers also decreases the rotational freedom of the lipid hydrocarbon chains. (De Gier et 
al., 1968). 
 
Liposomal formulations are good for topical application because they can spread 
excellently to form depots of active ingredients in the horny layer of the skin, which 
allows for the transport of dermatological and cosmetic agents of different types (Friberg 
et al., 1991; Wertz, 1992). Liposomes constitute a dermal drug delivery system that is 
non-irritating (Ceve, 1996), derma-cosmetically acceptable (Strauss and Pochi, 1965), 
and is relatively easy to prepare at a low cost (Banker and Rhodes, 1996). The 
encapsulation of actives like ampicillin and clindamycin in liposomes can help to reduce 
the toxicity and irritation caused by these actives (Lichtenberg and Barenholz, 1988). 
This is because the drugs are shielded in the liposomes, which are made up of substances 
similar to those present in cell membranes and are, therefore, regarded as biocompatible 
and biodegradable (Gabrijelcie et al., 1994). Moreover, the encapsulation of a drug in 
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submicron-sized liposomes may enhance drug penetration into the skin and reduce side 
effects (Soldo-Belic et al., 1999).  
 
Various groups (Gesztes and Mezei., 1988; Korting, 1992; Kato et al., 1987; Wohlrab 
and Lasch, 1987) have demonstrated that the adoption of a liposomal formulation can 
cause a 33% improvement in the transdermal penetration of clindamycin through the 
disruption of the multilamellar stratum corneum lipid structure (Bouwstra et al., 1992). 
However, liposome-mediated drug delivery has also been proposed to occur via the 
follicular pathway (Lauer et al., 1996), which leads to drug accumulation in the 
infundibulum and an improved drug efficacy. Indeed, animal studies have shown that 
clindamycin encapsulated in liposomes was able to penetrate into the stratum corneum 
and deeper skin layers, where the liposomes disintegrated and released the entrapped 
antibiotic. This formulation was noted to reduce the side effects of the drug e.g. stinging, 
erythema and contact dermatitis (Honzak and Sentjure, 2000). Topical liposomal 
preparations can also reduce the therapeutic dose required of corticosteroids and provide 
better control of the plasma drug concentration, again reducing the side effects of the 
drugs (Lasch et al., 1993).  
 
Liposomes as a delivery platform for BPO have been developed by various groups 
(Youssef et al., 1988; Couvreur et al., 1991; Bakker-Wuodenberg et al., 1986; Fattal et 
al., 1991; Bakker- Wuodenberg et al., 1985). It is anticipated that the change in dosage 
form from free BPO to liposome-encapsulated drug will result in significant improvement 
of clinical outcomes. For this change in clinical outcomes to be justified, the liposomal 
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formulations should meet the criteria of efficient drug encapsulation, control of the rate of 
drug release, and retention of antibacterial activity. According to several investigators 
(Mezei et al., 1980; Bonte et al., 1994; Touitou et al., 1994; Kim et al., 1997), liposomal 
formulations are indeed able to reduce the side effects of the various drugs encapsulated 
and are able to enhance the accumulation of the drugs at the administration site.  
 
Despite the scientific interest, the correlation between the liposome preparation method 
and the characteristics of the BPO-loaded liposomes remain poorly understood. (Patel et 
al., 2001). Depending on the methods of preparation, the BPO-loaded liposomes reported 
in the literature showed great variation in their physicochemical characteristics, such as 
size, size distribution, lamellarity, permeability, stability and encapsulation efficiency. It 
is important to understand how the manufacturing process influences the liposome 
properties because these characteristics affect the clinical efficacy of the formulation. The 
objectives of this project were, therefore, to develop, optimize and characterize BPO-
loaded liposomes prepared using the physical dispersion method, and to determine its 
antibacterial efficacy and its storage stability.  
 
The BPO-loaded liposomes were characterized for size, size distribution, efficiency of 
drug loading, and in vitro drug release profile. The average size and size distribution of 
liposomes are important parameters that impact on the physical properties and biological 
fate of the liposomes and their entrapped substances. These parameters affect the physical 
stability, in vivo distribution and size uniformity of the liposomal formulation. The 
determination of drug loading provides information on drug loss during preparation, as 
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well as the percent ratio of entrapped to free drug present in the formulation. The latter 
parameter can influence clinical drug bioavailability, which is estimated by the in vitro 
drug release profile in this study. Antibacterial assays were carried out to evaluate the 
effectiveness of the BPO liposomal formulation against P. acnes, while stability studies 
were conducted to determine whether the system underwent self assembling, fusion or 
phase change, and whether the antibacterial activity of the formulation was preserved 




















Benzoyl Peroxide (BPO), a therapeutic agent for acne, is known to induce concentration-
related skin irritation. Literature evidence suggests that the topical administration of BPO 
encapsulated in liposomes may be advantageous in reducing the irritation and itching 
associated with current BPO formulations. For this project, it is hypothesized that BPO 
can be successfully encapsulated in nano-sized liposomes that will preserve the stability 
and antibacterial activity of the drug.  
 
Experiments were designed in this study to fulfill the following objectives: 
(a)  Develop, optimize and characterize liposomal preparations of BPO using 
phospholipids and cholesterol as membrane components. 
(b) Determine the in vitro effectiveness of encapsulated BPO against P. acnes, the 
bacteria most commonly associated with acne.  






High-purity soybean phosphatidylcholine (PC) was from the Avanti Polar Lipids, Inc. 
(Alabaster, Al, USA). High purity cholesterol (CH), and benzoyl peroxide (BPO) (95% 
purity) were from the Sigma Chemical Company (St Louis, USA). Chloroform and 
acetonitrile (both of HPLC grade) were from Fisher Scientific (Fair Lawn, NJ, USA). 
Phosphate buffered saline (PBS, pH 7.4) was from the National University Medical 
Institutes (NUS, Singapore). Acetonitrile, o-phosphoric acid (85%, ACS grade) from 
Mallinckrodt Chemical (Phillipsburg, NJ, USA) and purified water obtained from a 
Millipore Milli-Q purification system (Millipore Corp., France) were used in the mobile 
phase for HPLC analyses. Propionibacterium acnes (P. acnes) from ATCC (American 
Type Culture Collection) (Virginia, USA) was cultured in reinforced clostridial medium 














4.1 Preparation of liposomes  
Multilamellar vesicles (MLVs) were prepared as previously described ( Lichtenstein and 
Margalit, 1995) from a lipid mixture of PC: CH at 3:1 mole ratio. Briefly, 200 mg of PC 
and 131 mg of CH (total lipid concentration of 3.3 mg/ml) were dissolved in 100 ml of a 
methanol:chloroform (2:1, v/v) solution in a round bottomed flask. BPO (1.885 mg) 
dissolved in 5 ml of chloroform (concentration of 0.377 mg/ml) was added to the lipid 
mixture to give a mole ratio of BPO: PC: CH at 1.5: 3: 1. The organic solvent was 
evaporated to dryness at pressures of 250 or 450 atm, with corresponding hydrating 
pressures of 100 and 150 atm, in a rotary evaporator (Laborota 4003, Heidolph, 
Germany) that was rotated at 180 r.p.m in a 40ºC water bath. When a thin film of lipid 
was deposited on the inner wall of the flask, phosphate buffered saline (PBS, pH 7.4, 5 
ml) was added and the preparation was rotated for a further 30 min until a white 
homogenous dispersion of liposomes was obtained. The dispersion was then incubated in 
a shaker bath (Shaker bath SB-16, Techni. NJ, USA, speed dial 4) for 2 h at 37ºC to 
complete the swelling process. Smaller MLVS were produced from the larger MLVs by 
probe sonication (Sonic, Newtown, Connecticut). Sonication was performed 
intermittently, with each cycle comprising of sonication at 40 W for 1 min followed by 1 
min of rest, and 10 - 100 of such cycles were applied to a batch of liposomes. The 
alternating cycle was to ensure that the liposomes were maintained at the ambient 
temperature of film hydration. The liposomes were incubated for another 2 h at 37ºC to 
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allow for the completion of the annealing process. Control (drug-free) liposomes were 
prepared in a similar manner except that the BPO was omitted.  
 
BPO-loaded liposomes employed for the antibacterial assay were prepared with BPO 
solutions of higher concentrations so that the theoretical final BPO loading concentrations 
in the liposomes would range from 12.5 to 100 mg/ml. These liposomes were formulated 
with PC: CH mole ratio of 3: 1 or 1: 1, the total lipid loading remaining at 16.5 mg for a 
5-ml dispersion of liposomes. In addition, the lipids were dried and hydrated at the 
pressures of 450 atm and 150 atm, respectively, and each batch of liposomes was 
subjected to 10 cycles of sonication for size reduction. 
 
All liposome dispersions were characterized immediately after preparation unless 
otherwise stated. The schematic flow chart for the preparation of liposomes is presented 
in Figure 1. 
 
4.2 Characterization of liposomes 
 
4.2.1 Quantitative BPO analysis with High Performance Liquid Chromatography 
(HPLC) 
BPO was quantitated using reversed-phase HPLC (United States Pharmacopoeia, 1995). 
The analysis was conducted in a Shimadzu system (LC 2010A, Kyoto, Japan) equipped 
with a C18 column from Phenomenex (30 x 4.6 mm, 5 µm pore size, Torrance, USA). 
BPO was detected spectrophotometrically at 254 nm. The mobile phase was composed of 
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70% v/v acetonitrile, 28% v/v water, and 2% v/v phosphoric acid. Analysis was carried 
out on 5 ml- samples, which were dissolved in 10 ml of methanol and made up to 20 ml 
with the mobile phase. After thorough mixing, the solution was filtered through a 400-nm 
disposable filter (Nucleopore, Whatman, Singapore) and 25 µl of solution was injected 
into the column. Under a flow rate of 1 ml/min, BPO had a retention time of 6.8 min. 
 
The HPLC was calibrated with BPO standard solutions in the concentration range of 10 – 
200 µg/ml (chloroform as solvent). A linear calibration plot (r2= 0.99) of peak area vs 
BPO concentration was obtained. Intraday and interday coefficients of variance were 
determined by analyzing triplicate samples of BPO standard solutions (50, 100 and 150 
µg/ml) thrice within a day and over 3 consecutive days, respectively.  
 
4.2.2 Encapsulation efficiency of BPO 
The efficiency of drug encapsulation (EE), defined in this project as the percentage of 
encapsulated BPO in a liposome dispersion (Equation 1), was determined as previously 
reported (Ganesan et al., 1984). Five-ml samples of liposomes were subjected to high-
speed centrifugation at 86,000 g for 4 h at 4ºC (Avanti J-25 centrifuge, Beckman Coulter, 
CA, USA). The supernatant containing the free drug was isolated, and the pellet 
containing the BPO-loaded liposomes was reconstituted in 5 ml of PBS. The BPO 
contents in the pre-centrifuged liposome sample, the supernatant and reconstituted pellet 
were determined by HPLC according to the method described in section 4.2.1. HPLC 
analysis was also performed on drug-free (control) liposomes, water and PBS.  
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EE was determined by 2 methods, termed the direct and indirect methods. In the direct 
method, the EE was the amount of drug present in the pellet calculated as a percent of the 
total drug present in the liposome dispersion prior to centrifugation (Equation 2). In the 
indirect method, the EE was calculated based on the amount of free drug present in the 
supernatant (Equation 3). Both methods were used to ensure mass balance, and to 
validate the calculation of EE.  
 
BPO encapsulation efficiency of the liposomal samples was calculated as follows: 
 
  Amt of drug encapsulated   
 % Encapsulation  =                                                                  × 100%  ---- Eq. 1 
                   Amt of BPO in formulation 
 
 
         Amt of BPO in pellet      
Direct method        =                                                   × 100% ---- Eq 2 
   Amt of BPO in precentrifugation sample 
 
    (Amt of BPO in precentrifugation sample – 
Amt of BPO in supernatant)  
Indirect method      =                                                                         × 100% --- Eq 3 







Drying down of lipids using rotary evaporator at 180 rpm, 40ºC (Step 1) 
 
 
Hydration of lipids using PBS followed by incubation in shaker bath for 2 h, 37ºC (Step 2) 
 
 
Probe sonication, followed by annealing for 2 h, 37ºC (Step 3)  
      
          




   
 Disperse in 5ml PBS 
Pellet Supernatant 
 





Figure 1.  Flow chart showing the processes involved in liposomal preparation 
and determination of BPO encapsulation efficiency 
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4.2.3 In vitro drug release 
The in vitro BPO release study was carried out over 24 h. Triplicate dispersions of 
liposomes (5 ml) were placed in separate dialysis sacs (molecular weight cut-off of 3,500, 
Spectra, Spectrum, Canada) immersed in glass bottles each containing 100 ml of stirred 
PBS (pH 7.4) (MR 3002, Heidolph, Germany, speed dial 4). At designated time periods 
(1/2 h, 1 h, 3 h, 5 h, 8 h, 24 h), 1-ml aliquots were removed from the receptor 
compartments and replaced with an equal volume of PBS. Drug concentration in the 
receptor compartment was determined by HPLC. The in vitro BPO release profile was 
constructed by plotting the mean cumulative percent drug release (calculated based on the 
actual BPO content in the liposomes) against time.  
 
4.2.4 Size, size distribution and morphology 
Each batch of liposomal dispersion was characterized by the mean particle diameter and 
size distribution using a zetasizer (Malvern Instruments Ltd, Worcs, U.K.). Triplicate 
batches were analyzed immediately upon preparation.    The morphology of the 
liposomes was observed under a transmission electron microscope (TEM) (CM 100, 
Philips, Japan). Each liposomal sample, supported on a copper grid, was stained with 5% 
phosphotungstic acid prior to observation under the TEM.  
 
4.3 In vitro inhibition of P. acnes  
Liposomal samples prepared with lipids PC:CH in the ratio of 3:1 and 1:1, and having 
theoretical BPO concentrations of 12.5, 25, 50 and 100 mg/ml were used for the 
antibacterial assay (Table 2). Control samples included BPO solutions prepared by 
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dissolving BPO in chloroform in the concentration range of 12.5 to 100 mg/ml. In 
addition, control drug-free liposomes and solutions of the lipids, PC and CH dissolved in 
chloroform in the molar ratio of 3:1 and 1:1, were also evaluated.   







L31B0 Liposomes 3:1     0.0 
L31B12.5 Liposomes 3:1   12.5 
L31B25 Liposomes 3:1   25.0 
L31B50 Liposomes 3:1   50.0 
L31B100 Liposomes 3:1 100.0 
L11B0 Liposomes 1:1     0.0 
L11B12.5 Liposomes 1:1   12.5 
L11B25 Liposomes 1:1   25.0 
L11B50 Liposomes 1:1   50.0 
L11B100 Liposomes 1:1 100.0 
S0B12.5 Solution  Nil   12.5 
S0B25 Solution Nil   25.0 
S0B50 Solution Nil   50.0 
S0B100 Solution Nil 100.0 
S31B0 Solution 3:1     0.0 




4.3.1 Culture of P. acnes 
One loopful of freeze dried P. acnes was withdrawn under anaerobic conditions of 85% 
N2 : 10% CO2 : 5% H2 (Bactron Anaerobic Environmental Chamber, Sheldon 
Manufacturing, USA) and transferred into one tube of reinforced clostridial medium (20 
ml) to form the reconstituted bacterial suspension. After careful mixing, 0.5-ml aliquots 
of the bacterial suspension were transferred to tubes containing 20 ml of reinforced 
clostridial medium. The tubes were then incubated under anaerobic atmosphere at 37°C. 
In 48 – 72 h, bacterial growth was evident by the presence of turbidity and sediment in 
the media. These bacterial culture broths were used to inoculate agar plates for the 
antibacterial assay described in section 4.3.2. 
 
4.3.2 Antibacterial Assay 
The preparations of solutions and materials, as well as the assay itself, were performed 
under aseptic anaerobic conditions. The assay was performed according to the cup plate 
method where bored out cups were prepared in the agar plates for holding the test 
samples. 25-ml universal bottles containing 20 ml of agar at concentration of 47 g/l were 
prepared 1 day in advance and stored at 4°C until use. On the day of an assay, agar in the 
universal tubes was liquefied by autoclaving (Hiclave HV-50, Hirayama, Japan) and the 
liquefied agar was equilibrated to 45°C by incubation for 1 h in a water bath (Grant 
Instruments, England). The liquefied agar was then added at 20 ml into each petri dish 
and thoroughly mixed with 2.5 ml of the bacterial culture broth (section 4.3.1). After the 
agar had hardened at ambient conditions, 6 cups were aseptically created in the agar plate 
using a borer of diameter 1 cm. The cups were labeled from A to F (Figure 2.2). Test and 
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control samples, sterilized by exposure to UV light (Quest Instruments, USA) overnight, 
were added at 1 ml into the agar cups according to the predetermined scheme in Figure 
2.2. Control plates included agar without bacteria inoculation, agar without bacteria 
inoculation but in which BPO liposomes or solutions had been added, and agar with 
bacteria inoculation but without the addition of BPO samples. The agar plates were then 
incubated anaerobically for 72 h at 37°C. Experiments were conducted in quadruplets.  
 
After the incubation period, each agar plate was inverted over a dark background and the 
diameters of the growth inhibition zones around each cup were measured with a vernier 
caliper accurate to 0.01 mm (244 High Holborn, C. Baker, London). The diameter of the 
cup was measured, then subtracted from the zone of inhibition (D1) and divided by 2 to 
obtain the value of d (i.e. the distance from the edge of the cup to the edge of the zone of 
inhibition) (Figure 2.1). Two measurements were made for each cup, with one diameter 
measured at right angles to the other, and the average value was recorded as the zone of 
inhibition.  
 
       d                                                                       
 
 
              
      
 
Figure 2.1. Determination of the zCup   D1
one of inhibition for each cup on the agar plate.  
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A Solution or liposomes with 100 mg/ml of BPO 
B Solution or liposomes with 50 mg/ml of BPO 
C Solution or liposomes with 25 mg/ml of BPO 
D Solution or liposomes with 12.5 mg/ml of BPO 
E* Empty Liposomes 
F* Lipids dissolved in chloroform 
 
*Cups absent in plates used for BPO solution 





4.4 Stability of liposomes 
The stability of the liposomal preparations was evaluated as a function of storage time. In 
the preliminary experiments, six batches of liposomal samples were stored in a 
refrigerator (Kelvinator, EKA,USA) at 4ºC for 3 months immediately after preparation. 
Once every 2 weeks, the size and size distribution of the samples were determined using 
the method described in section 4.2.4.  
 
Liposomes prepared with PC:CH mole ratio of 3:1 or 1:1, and with BPO loading 
concentrations of 12.5 to 100 mg/ml were also evaluated for their storage stability. These 
liposomes were stored immediately after preparation for 3 weeks in the refrigerator or at 
ambient conditions (21ºC) in 50ml disposable plastic tubes (National University Medical 
Institutes, NUS, Singapore). The size, size distribution and morphology of the liposomes 
before and after storage were evaluated using the particle sizer and the TEM, respectively 
(section 4.2.4). Storage-induced changes to the percent of BPO encapsulated within the 
liposomes were monitored using the methods described in section 4.2.2. In addition, the 
antibacterial efficacy of the liposomal formulations as a function of storage conditions 
was determined using the assay described in section 4.3. 
 
4.5 Statistical analysis 
Data are presented as mean ± standard deviation. Values for encapsulation efficiencies 
were analyzed using the t-test (paired). Values of p ≤ 0.05 were indicative of significant 
differences. Variation in the BPO content in the liposomes as a result of variations in 
processing conditions, and variation in the zones of inhibition on the agar plates used in 
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the antibacterial assays, were analyzed by two-way ANOVA and least significance 
difference tests using SPSS 10, SPSS Inc. Chicago, IL, USA (p = 0.05). 
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5. Results and Discussion 
 
5.1 Preliminary Experiments 
Formulation and process parameters are known to strongly affect the properties of drug-
loaded liposomes. As with all drug delivery systems, a precise characterization of the 
physico-chemical parameters of the BPO-loaded liposomes is important in order to 
develop drug products of high quality. The parameters used to characterize the liposomes 
in the preliminary experiments included particle size and morphology, the drug loading 
and encapsulation efficiency and the drug release profile. Stability studies using particle 
size as an indicator of stability were also conducted over a 3-month period.  
 
Liposome Preparation 
Table 3 shows the size distribution of multilamellar blank and BPO-loaded liposomes 
prepared using different sonication times. The BPO-loaded liposomes were made from 
the addition of 0.012 ml of BPO solution (0.377 mg/ml) to 5 ml of a solution of PC:CH in 
the mole ratio of 3:1 (solvent consisted of 2:1 v/v of chloroform and methanol). The 
resultant mole ratio of BPO: PC: CH was 1.5: 3: 1. The blank liposomes were prepared 
without the addition of BPO solution. In all cases, the organic solvents were evaporated 
to dryness at 450 atm and the lipids were hydrated with 5 ml of PBS for 30 min. The 
resultant dispersion was incubated in a shaker bath for 2 h at 37ºC, after which it was 
sonicated and sized with the zeta sizer.  
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Liposomes in the size range of 200 – 300 nm, which were obtained over 60 - 100 min of 
repeated sonication and cooling, are desirable because of their increased stability 
compared to larger vesicles (Ho et al., 1995; Zulli and Suter, 1994; Lasic, 1997). 
However, because of the long processing time and the fact that the maximum amount of 
drug incorporated into liposomes was dependent on the quantity of membrane 
components rather than on the size of the liposomes (Wendel, 1997; Braun-Falco et al., 
1992), subsequent batches of liposomes were sonicated for 10 min. Under these 
processing conditions, the control blank liposomes and BPO-loaded liposomes had mean 
sizes of about 500 nm and 700 – 900 nm, respectively.  
 
Annealing was performed on the prepared liposomes to prevent physical degradation and 
drug loss (Uster, 1990). This process involved incubating the liposome dispersion for 2 h 
at 35ºC, a temperature higher than the phase transition temperatures of the lipids PC (at 
35°C) and CH (27ºC) (http://www.avantilipids.com/PreparationOfLiposomes.html, 
2003), to allow for the equilibrium of opposite sides of the lipid bilayer by 
transmembrane flip-flop (Schafer-korting et al., 1989). To prevent contamination from 
particles during ultracentrifugation, PBS was filtered through a 100-nm disposable filter 
(Nucleopore, Whatman, Singapore) prior to its use as a hydrating solution.  
 
Table 3. Effects of sonication duration on the size distribution of liposomes 
 Blank liposomes BPO-loaded liposomes 
Sonication 
time (min) 




509 ± 16 230 ± 32 251 ± 16 936 ± 286 534 ± 29 260 ± 68 
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HPLC Assay 
Pure BPO and BPO recovered from liposomes both showed a retention time of 6.8 min 
when analyzed using the established HPLC method. In contrast, the control systems, such 
as water, PBS and blank liposomes, did not show any HPLC peaks within the elution 
time frame of 10 min. The calibration plot of peak area against concentration for the BPO 
standard solutions showed good linearity in the concentration range of 10 – 200 µg/ml (r2 
= 0.99) (Appendix 1). The intra- and inter-day coefficients of variation, determined using 
3 batches of BPO liposomal samples, were less than 4.5% (Appendix 2), indicating that 
the analytical method was robust.  
 
Encapsulation Efficiency 
The encapsulation efficiency (EE) was defined as the percentage of BPO in a formulation 
that was encapsulated within the liposomes, and was determined using both the direct and 
indirect methods as explained in section 4.2.2. Table 4 shows the EE for BPO-liposomes 
prepared with the PC:CH mole ratio of 3:1 and with BPO concentration of 0.377 mg/ml. 
For batch 1, the drying down pressure was applied at 250 atm, with corresponding 
hydration pressure at 100 atm, and the liposomes were sonicated for 10 min after 
hydration with PBS. To extract the BPO from the liposomes, the scheme as depicted in 
Figure 1 was followed, with 10 min manual shaking applied as the agitation method (Step 
5, Figure 1). Under these processing conditions, >90% of the BPO in the liposome 
formulations was found to be encapsulated in the liposomes (Batch A), and there were no 
statistical differences between the EE values derived by the direct and indirect methods of 
calculation (p = 0.65, student t-test).  
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Table 4.  BPO encapsulation efficiency (EE, %) of liposomes prepared with 
different drying and hydration pressures. EE was calculated from the 
BPO contents in the liposomal dispersion before (precentrifugation 
sample) and after centrifugation (pellet and supernatant). (Values 














A 515 ± 36 477 ± 42 20 ± 16 96 ± 3 93 ± 3 
B 1530 ± 26 1397 ± 40 84 ± 22 95 ± 2 91 ± 1 
1Batch A was produced at drying down pressure of 250 atm and corresponding hydration 
pressure of 100 atm; while Batch B was produced at drying down pressure of 450 atm 
and corresponding hydration pressure of 150 atm. 
 
Despite the favorable EE values, there was, however, a large difference between the 
amount of BPO used to prepare the liposomes (1894 µg) and the amount of BPO found in 
the pre-centrifugation samples (below 550 µg) (Table 4). The recovery rate was less than 
30%.  
 
To determine the factors that contributed to the BPO loss, several experiments were 
conducted. In the first set of experiments, the BPO contents in the distillate and residue 
obtained following rotary evaporation, and BPO content in the liposomal dispersion 
obtained by hydrating the residue with PBS (Step 2, Figure 1) were measured to 
determine the contribution of post-evaporative processing to the total BPO loss. In the 
next set of experiments, which sought to determine if the method and duration of 
agitation (Step 5, Figure 1) contributed to BPO loss, triplicate batches of liposomes were 
prepared, and each batch separated into 2 portions. One portion was subjected to manual 
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agitation and the other to probe sonication to break down the liposomes into smaller 
particles, and the BPO content in the dispersions was assayed at specific time points of 
agitation. The recovery rate was calculated by expressing the BPO content as a percent of 
the BPO load used to prepare the liposomes. The third set of experiments was conducted 
to examine the role that filtration (Step 6, Figure 1) played in contributing to the BPO 
loss during liposomal preparation. BPO loss was calculated by determining the BPO 
content in a batch of liposomes before and after filtration using a filter of 400 nm pore 
size (Nucleopore, United States Equipment).  
 
Table 5 shows that the drying down process removed a substantial 44.6% (867 µg) of the 
BPO load used to prepare a batch of liposomes. Post-evaporation processing, which 
consisted of probe sonication, ultracentrifugation, extraction and filtration processes 
(Figure 1), removed another 11.3%, leaving about 46.9% (913 µg) of the initial BPO load 











Table 5.  Loss of BPO due to rotary evaporation and post-evaporation 















Amount (µg) 1945 1029 867 913 
BPO loss due to 
evaporation 
              867/1945 x 100% = 44.6% 
BPO loss due to 
post-evaporation 
processing 
(1029 – 913)/ 1029 x 100% = 11.3% 
BPO content in 
liposome samples 
               913/1945 x 100% = 46.9% 
 
For the second set of experiments, it was hypothesized that the extraction of encapsulated 
BPO from the liposomes was dependent on the method of agitation used during drug 
extraction into the organic phase (Step 5, Figure 1). If the chosen method of agitation 
could disrupt more liposomes, a greater amount of encapsulated BPO would be released 
for HPLC quantification. To determine the effects of the method and duration of agitation 
on the quantification of BPO content in the liposomes, control BPO solutions and BPO-
loaded liposomal dispersions were subjected to manual shaking and probe sonication for 
up to 20 min after mixing with the organic solvents. The control BPO solutions were 
prepared using the same method as the BPO-loaded liposomes except that the lipids were 
omitted. High recovery rates were obtained for the BPO solutions whereas the recovery 
rates for the BPO-loaded liposomes processed by either agitation method were 
significantly lower than the corresponding recovery rates for the BPO solutions (Table 6). 
However, analysis of the recovery data by 2-way ANOVA for the BPO-loaded liposomes 
indicated that the method and duration of agitation did not significantly affect the 
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recovery of BPO from the liposomes (p > 0.05). In subsequent experiments, the 
encapsulated BPO was extracted by manual agitation with the organic solvents for 10 
min.  
 
The results of the third set of experiments showed that the recovery rates of BPO for both 
the BPO solution and the BPO encapsulated liposomes were not affected by the process 
of filtration (Table 7). High recovery levels exceeding 95% were obtained for the BPO 
solution while BPO recovery for the liposomes before and after filtration were, as 
expected, lower than corresponding values for the solutions. However the collective data 
suggest that the differential recovery was not contributed by the process of filtration. 
 
 
Table 6. Effects of the method and duration of agitation on the recovery of BPO (%) 
from BPO solutions and BPO-loaded liposomes. Recovery was determined 
by expressing the BPO content as a percentage of the BPO load (~950 µg) 
obtained post-evaporation in the solution and liposomes samples. (Mean ± 
SD, n = 3) 
 
BPO solution BPO-loaded liposomes Duration (min) 
Manual 
Agitation (%) 
Sonication (%) Manual 
Agitation (%) 
Sonication (%)
5 97.1 ± 3.3 89.6 ± 4.9 72.4 ± 7.5 62.9 ± 8.6 
10 99.2 ± 6.3 91.9 ± 5.9 75.1 ± 3.7 60.5 ± 1.6 
15 89.8 ± 4.7 88.3 ± 9.6 71.6 ± 3.7 58.5 ± 3.6 











Table 7.  Effect of filtration on the recovery of BPO from BPO-loaded liposomes 
and BPO solutions. Recovery was calculated as a percent of the initial 



















recovered   
(µg) 
942 ± 6 940 ± 7 708 ± 5 745 ± 3 
Recovery (%) 98 ± 3 97.9 ± 4 75 ± 3 79.2 ± 2 
 
The results of the 3 series of experiments indicated that the processes of drying down and 
hydration of the lipids contributed to the most significant BPO loss. In order to reduce the 
BPO loss through this process, the pressure applied was increased from 250 to 450 atm 
during the drying down process, and from 100 to 150 atm during the hydration of the 
lipids. Although this significantly prolonged the total duration of the two processes from 
2 to 7 h, the evaporation of chloroform occurred at a much gentler pace, and the recovery 
of BPO in the residue improved significantly, from 52.8% to 91.58% (Table 8). 









Table 8.  The effect of pressure applied during rotary evaporation on the loss of 
BPO from the liposomes. Recovery was calculated based on the initial 
BPO load of ~1800 µg. (Mean ± SD, n = 3) 
 
1Low pressure = 250 atm applied for solvent evaporation. 
Low pressure1 High pressure2 
Distillate Residue Distillate Residue 
Amount of 
BPO (µg) 
840.5 ± 86.0 950.2 ± 101.0 151.5 ± 49.0 1619.0 ± 93.0 
Recovery % 46.6 ± 1.6 52.8 ± 2.7 8.4 ± 0.9 91.6 ± 3.4 
2High pressure = 450 atm applied for solvent evaporation. 
 
 
Table 4 shows the EE obtained for liposomes prepared with the higher operating 
pressures. The EE values remained at >90%, similar to values obtained for liposomes 
prepared with the lower operating pressures, suggesting that most of the BPO in the 
liposomal dispersion remained encapsulated in the liposomes. However, what was 
noteworthy was the significant improvement in the total BPO content in the liposomal 
dispersion. BPO recovery was 85% with respect to the initial BPO load used to prepare 
the liposomes. Thus, the improved protocol had reduced the BPO loss from about 75% to 
about 15%, which is acceptable given the various processing steps involved in the 
preparation of the liposomes and the determination of EE.  
 
In vitro drug release profile 
The in vitro BPO release study was carried out to determine how the difference in the 
size of the liposomes affected the amount of drug released. This study was carried out 
over a period of 24 h using 5 ml of liposome dispersions incubated in a dialysis sac. 
Experiments were conducted in triplicates. The method adopted for preparing the 
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liposomes for this study was similar to that described for Batch B (Table 4), except that 
the duration of sonication was varied from 0 min (B-0), to 10 min (B-10) and 20 min (B-
20).  
 
Figure 3 shows the in vitro BPO release profiles of B-0 (mean particle size of 1300 ± 
90nm), B-10 (700 ± 50nm) and B-20 (350 ± 70nm) liposomes. BPO solutions prepared in 
a similar manner but with the omission of lipids served as controls. To evaluate if the 
dialysis sac hindered the effective transport of BPO between the donor and receptor 
compartments, parallel release experiments were conducted of the BPO solutions in the 































Figure 3.  In vitro release profiles of BPO from liposomes produced with 
different duration of sonication: 0 min (B-0), 10 min (B-10) and 20 
min (B-20). Control experiments were conducted with BPO solutions 
in the presence (C-1) and absence (C-2) of the dialysis bag. (Mean ± 




The release rate of BPO from the liposomes increased gradually over 24 h and may be 
ranked in the order of B-20 < B-10 < B-0, i.e. the bigger the liposomes, the faster the rate 
of release of BPO. This surprising phenomenon can be explained after the particles were 
observed under the TEM. TEM microphotographs (Figure 4) showed the B-20 sample to 
be heterogeneous and to contain particle aggregates of various sizes, whereas the B-10 
sample, which was subjected to a shorter duration of sonication, was a relatively 
homogeneous sample consisting of discreet, spherical particles with a dense structure. 
The propensity of the B-20 sample to aggregate into larger particles would give rise to 
smaller surface area to volume ratio, which would slow down the rate of release of the 
encapsulated BPO. Figure 3 also shows that the BPO-loaded liposomes exhibited 
sustained release, having less than 40% of the encapsulated BPO released into the 
receptor compartment after 24 h. In contrast, more than 90% of the BPO load in solution 
was detected in the receptor compartment within 30 min of incubation. The presence of 
the dialysis sac did not interfere with the transport of BPO from the donor to the receptor 
compartment, because comparable BPO release profiles were obtained of the control 









                                           
(a)                                                                                             (b) 
     
                                       
(c)                                                                                              (d) 
Figure 4.  TEM photomicrographs of liposomes prepared with 10 min (B-10) (a 
and b) and 20 min (B-20) (c and d) sonication. Liposomes were 




Stability under storage  
Preliminary studies on the storage stability of BPO-loaded liposomes were conducted 
using particle size as an indicator of stability. Using similar conditions of preparation as 
those of batch B (Table 4), one batch (designated as Batch 6, mean particle size of 786 ± 
147 nm) was produced without sonication, while the other 5 replicate batches (Batches 1 
– 5, mean particle size of 175 nm to 480 nm) were produced with 100 min of sonication. 
Analysis of the size distribution data by 2-way ANOVA indicated a significant difference 
(p < 0.05) between batch 6 and the other batches, but not amongst batches 1-5 (p > 0.05). 
All 6 batches of liposomes were stored at 4°C for the stability studies.  
 
Figure 5 shows the change in mean particle size for the 6 batches of liposomes as a 
function of storage time. Although the particle size for all 6 batches of liposomes changed 
upon storage at 4°C, batch 6 exhibited the greatest erratic change in size distribution with 
storage time. This suggests that liposomes prepared without sonication might be less 
stable. Batches 1-5 showed more modest size changes compared to batch 6, with a 
general progression towards larger mean vesicle diameter. This may be due to the 
coalescence and aggregation of lipids in the aqueous environment to form larger 





























Figure 5.  Mean particle size of BPO-loaded liposomes after storage at 4°C for 
various period of time. Batch 6 was prepared without sonication. 
Batches 1 to 5 were prepared with 100 min sonication.  
 
 
5.2 Effects of Drug Loading 
For the preliminary experiments, liposomes were prepared to have theoretical BPO 
loading concentrations in the range of 0.25 - 5 µg/ml. However, an initial antibacterial 
screening experiment using the agar plate method found that BPO dissolved in 
chloroform at this concentration range was ineffective in inhibiting the cultured P. acnes. 
Moreover, the MIC for BPO has been stated in the literature to be in the range of 2.5 to 
10 %w/v. Thus, subsequent batches of liposomes were prepared to contain higher BPO 
loading concentrations in the range of 12.5 – 100 mg/ml (equivalent to 1.25 – 10% w/v). 
This concentration range compares favorably with that found in commercial preparations 
of BPO gels (2.5% to 10% w/v). Another change in the formulation was instituted 
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following the finding that the BPO liposomes prepared with the lipid mixture of PC: CH 
in the mole ratio of 3:1 were unstable after storage (Table 11). The PC:CH ratio was 
changed to 1:1 following a survey of the literature which indicated that liposome stability 
might be enhanced by increasing the cholesterol content in the bilayers (De Gier et al., 
1968). A summary of the batches of liposomes prepared for this section are listed in 
Table 2. 
 
5.2.1 Characteristics of liposomes 
 
Liposomal size distribution 
Table 9 shows the size distribution of freshly prepared liposomes formulated with PC: 
CH in the mole ratios of 3: 1 and 1:1. The size distribution of the liposomes lies in the 
range of 700 – 800 nm, irregardless of BPO concentration. In addition, the size of BPO 
liposomes prepared with higher CH content was not significantly different from that of 
liposomes prepared with PC:CH ratio of 3:1 (p > 0.05, 2-way ANOVA). TEM studies 
further confirmed that the size distribution of BPO liposomes prepared with the two PC: 
CH ratios (Figure 6) did not differ significantly. Under the TEM, liposomes from both 
series of formulations appeared globular in shape and were relatively homogeneous in 






Table 9.  Effect of BPO concentrations: 0 mg/ml (B0), 12.5 mg/ml (B12.5), 25 
mg/ml (B25), 50 mg/ml (B50), and 100 mg/ml (B100) on the size 
distribution of liposomes prepared with the lipids PC: CH in the ratio 
of 3:1 (L31) and 1:1 (L11). Values represent mean size ± SD, n = 3. 
 
        BPO 
 
PC:CH 
B0 B12.5 B25 B50 B100 
L 31 704 ± 32 736 ± 51 710 ± 37 706 ± 61 691 ± 47 
L11 764 ± 51 836 ± 61 800 ± 17 746 ± 81 731 ± 37 
                                        
200 nm 200 nm 
  
                        
(a)                                                                                     (b) 
Figure 6.  TEM photomicrographs of liposomes (B0) prepared with the lipids 
PC:CH in the ratio of 3:1 (a) and 1:1 (b). Liposomes were observed at 







BPO Encapsulation efficiency 
Table 10 gives the EE of BPO liposomes prepared with PC:CH in the mole ratios of 3:1 
and 1:1. Compared with liposomes containing the lower BPO loading of 0.377 mg/ml, 
which had EE > 90% (Table 8), liposomes with higher BPO contents had reduced EE. 
The EE for liposomes prepared with PC:CH mole ratio of 3:1 ranged  between 71% to 
78% while those for liposomes prepared with PC:CH mole ratio of 1:1 ranged between 
74% to 83% (Table 10). The lower EE values might be the result of a lower proportion of 
CH:BPO in the new formulations. Interaction between cholesterol and the fluid lipid 
chains is proposed to increase the order and packing density of the lipids in liposomes, 
thereby stabilizing the lipid bilayer (De Gier et al., 1968) and decreasing its mobility and 
permeability (Lasic, 1993). The addition of CH could therefore limit the loss of 
encapsulated materials from liposomes (Ganapathi, 1984). On this basis, less BPO might 
be encapsulated in formulations with lower CH:BPO content. This argument holds well 
when, at equivalent BPO loading, the EE value for the liposomes was found to increase 
significantly (p < 0.05, 2-way ANOVA) with increasing PC:CH ratio from 3:1 to 1:1 
(Table 10). However, the argument cannot explain the discrepancy observed when the EE 
of the liposomes did not decrease when the BPO concentration was increased from 12.5 
to 100 mg/ml. Regardless of the PC:CH ratio used, an increase in BPO loading 
concentration would reduce the CH:BPO ratio in the liposomes, yet liposomes prepared 
with PC:CH ratios of 3:1 and 1:1 showed insignificant variation in EE with increasing 




Table 10.  BPO encapsulation efficiency (EE, %) of liposomes prepared with 
PC:CH mole ratios of 3:1 or 1:1, and with BPO loading 
concentrations of 12.5, 25, 50 or 100 mg/ml. EE was calculated from 
the BPO contents in the liposome dispersion before (precentrifugation 
sample) and after centrifugation (pellet and supernatant). Values 
represent Mean ± SD, n = 3. 
 
BPO content after 
















L31B12.5 9528 ± 40  7470 ± 60 2152 ± 126 77 ± 1  78 ± 2 
L31B25 18756 ± 130  14480 ± 63 4456 ± 88 76 ± 3  77 ± 2 
L31B50 33896 ± 208 25832 ± 861 8393 ± 190  75 ± 3 76 ± 2 
L31B100 74646 ± 249 54827 ± 600 21543 ± 84 71 ± 3 73 ± 4 
L11B12.5 11430 ±242 9551 ±159 2030 ±90 82 ± 1 84 ± 1 
L11B25 23002 ± 348 17041 ± 286  4333 ± 331 79 ± 2 81 ± 2 
L11B50 37940 ± 260 29711 ± 325 8445 ± 318 78 ± 3 78 ± 2 
L11B100 75000 ± 154 56513 ± 343 19365 ± 130 74 ± 2.35 75 ± 3 
*Refer to Table 2 for formulation details. 
 
In vitro drug release profile 
In vitro BPO release profiles are shown in Figures 7 and 8 for the liposomes prepared 
with PC:CH mole ratios of 3:1 and 1:1, respectively. After an initial burst effect, in which 
about 15% of the encapsulated BPO was released within 1 h, the release of BPO 
increased linearly with time for up to 24 h, suggesting a zero-order release profile (R2 = 
0.985). Compared to the equivalent BPO solutions, the liposomal formulations again 
exhibited sustained drug release. Comparable in vitro BPO release profiles were obtained 
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for all the batches of liposomes, with cumulative percent of BPO released after 24 h 
being about 50%. Thus, the BPO loading concentration and PC:CH mole ratio did not 
appear to affect the rate of release of BPO from the liposomes.  
 
For BPO liposomes prepared with PC:CH ratio of 3:1, the percentage cumulative BPO 
released after 24 h was about 50% for all batches, higher than the 40% determined for the 
liposomes prepared for the preliminary experiments, which had much lower BPO loading 
of 0.377 mg/ml. One possible reason could be that, when the BPO concentration was very 
low, the drug could exist in the molecular form, whereas in the loading concentration 
range of 12.5 to 100 mg/ml, the solubility of BPO in the liposomes could be exceeded 
and the drug existed in the crystal form. The crystalline drug would take a longer time to 
be released from the liposomes, having first to dissolve before it could diffuse out of the 
liposomes. The release profiles could also be related to the lower EE of liposomes 
formulated with the higher BPO concentrations. With less BPO encapsulated, more of it 
would readily diffuse into in the dialysate and account for a larger proportion of BPO 


































Figure 7.  In vitro release profiles of BPO from liposomes produced with lipids 
PC: CH in the ratio of 3:1 and with different BPO concentrations: 
12.5 mg/ml (L31B12.5), 25 mg/ml (L31B25), 50 mg/ml (L31B50) and 
100 mg/ml (L31B100). Control experiments were conducted with BPO 
solutions of different concentrations: 12.5 mg/ml (S0B12.5), 25 mg/ml 






































Figure 8.  In vitro release profiles of BPO from liposomes produced with lipids 
PC: CH in the ratio of 1:1 and with different BPO concentrations: 
12.5 mg/ml (L11B12.5), 25 mg/ml (L11B25), 50 mg/ml (L11B50) and 
100 mg/ml (L11B100). Control experiments were conducted with BPO 
solutions of different concentrations: 12.5 mg/ml (S0B12.5), 25 mg/ml 
(S0B25), 50 mg/ml (S0B50), 100 mg/ml (S0B100). (Mean ± SD, n = 3).  
 
 
5.2.2 Microbiological Activity 
Upon incubation for 72h under anaerobic conditions, there were tiny, white, glistening, 
circular colonies of bacteria characteristic of P. acnes colonies (Marples, 1974) present 
on agar plates inoculated with the bacteria. This indicated that the bacteria was viable, 
and was able to proliferate under the experimental culture conditions. Agar plates which 
were not inoculated with P acnes, but to which the BPO liposomes prepared with PC:CH 
mole ratio of 3:1 and 1:1 were added, did not exhibit any bacteria colony under the same 
incubation conditions. Agar plates which were inoculated with P. acnes and treated with 
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either BPO solutions or BPO-loaded liposomes exhibited clear zones of inhibition around 
the sample cups, suggesting that BPO was effective in inhibiting the growth of P. acnes.  
 
The zones of inhibition vs. BPO concentration for the BPO solution and BPO-loaded 
liposomes are shown in Figure 9. No zone of inhibition was observed for cups containing 
preparations with BPO loading concentration below 12.5 mg/ml. For samples with BPO 
concentration of 25 mg/ml or higher, the zones of inhibition increased with the BPO 
concentration, particularly for the liposomal formulation. Comparable zones of inhibition 
were obtained for BPO liposomes prepared with different PC:CH ratios of 3:1 and 1:1, 
which corroborated with the in vitro BPO release profiles of the liposomes.  However, the 
BPO liposome formulations produced significantly smaller zones of inhibition compared 
with the corresponding BPO solution formulations, implying that BPO in solution was 
more effective at inhibiting the bacteria growth than encapsulated BPO in liposomes. A 
reason could be the greater availability of BPO, as seen in the in vitro release profiles 
(Figure 7 and 8). Nevertheless, it was noted that, even for the BPO solutions, no zone of 

























Figure 9. Zones of inhibition against P. acnes for BPO-loaded liposomes prepared 
with PC:CH mole ratios of 3:1 (L31B) and 1:1 (L11B), and the control 














5.3 Effect of Storage 
 
5.3.1 Characteristics of Liposomes 
 
Size distribution 
After 3 weeks of storage at 4°C, the BPO-loaded liposomes prepared with the PC: CH 
ratio of 3:1 were found to increase in mean size from about 800 nm to more than 2000 
nm. In contrast, corresponding BPO liposomes stored for 3 weeks at room temperature 
decreased in size to between 200 – 400 nm. TEM micrographs of the liposomes stored in 
the fridge typically showed irregularly shaped particles that appeared to be agglomerates 
of smaller particles (Figures 10a and b), while liposomes stored at room temperature 
retained their spherical shape but appeared smaller in size (Figures 10c and d). Storage at 
either temperatures also caused the liposomes with higher BPO loading concentrations to 
have significantly larger mean size than those with lower BPO content. 
 
Increasing the cholesterol content by raising the PC:CH ratio in the lipid bilayers to 1:1 
led to improved storage stability for the BPO-loaded liposomes. Although liposomes 
prepared with PC:CH ratio of 1:1 also increased in size upon storage at 4°C and room 
temperature (Table 15), the storage-induced changes in size were small compared to 
those seen in liposomes with PC:CH ratio of 3:1. In addition, the BPO loading 
concentration and the storage temperature exerted smaller influences on the post-storage 
size distribution of the liposomes prepared with PC:CH ratio of 1:1. Mean size 
differences attributed to BPO loading concentration and storage temperature were not 
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found to be statistically significant (p > 0.05, 2-way ANOVA). Because of the instability 
of the liposomes prepared with PC:CH ratio of 1:3, subsequent studies on drug 
encapsulation efficiency, in vitro drug release and antibacterial assay against P. acnes 
were conducted with liposomes with PC:CH ratio of 1:1. 
 
 
Table 11. Effect of storage on the mean size (nm) of BPO-loaded liposomes prepared 
with PC:CH ratio of 3:1 and 1:1. Liposomes were stored for 3 weeks at 









704 ± 32 736 ± 51 710 ± 37 706 ± 61 691 ± 47 
















764 ± 51 731 ± 37 746 ± 81 800 ± 17 836 ± 61 
Fridge 920 ± 3 892 ± 
92 
884 ± 96 979 ± 47 1154 ± 67 
Room 
Temperature 
1185 ± 9 820 ± 
12 


















(a)       (b) 





(c)                                                                            (d) 
Figure 10.  TEM photomicrographs of liposomes prepared with lipids PC:CH in 
the ratio of 3:1 and BPO loading concentration of 25 mg/ml. 
Liposomes had been stored for 3 weeks at 4°C (a and b) and at room 
temperature (c and d) before TEM analysis at magnification of 28.5K 






BPO encapsulation efficiency 
After 3 weeks of storage at either 4°C or room temperature, the EE of liposomes with 
PC:CH ratio of 1:1 was found to fall by 13 to 18% to reach values of 60% to 65% (Table 
12). As the total BPO content in the pre-centrifuged samples had not changed 
significantly with storage (p > 0.05, 2-way ANOVA), the decrease in EE could not be 
attributed to storage-induced BPO degradation. It is more likely that the equilibrium 
between free and encapsulated BPO in the liposomal formulations had shifted due to the 
diffusion of encapsulated BPO out of the liposomes with time. This is further confirmed 
by the results of subsequent in vitro drug release studies (Figures 6 and 7). The storage 
temperature and BPO loading concentration did not significantly affect (p > 0.05, 2-way 














Table 12.   BPO encapsulation efficiency (EE, %) of liposomes prepared with PC: 
CH in the mole ratio of 1:1 and BPO concentrations of 12.5 mg/ml 
(L11B12.5), 25 mg/ml (L11B25), 50 mg/ml (L11B50), 100 mg/ml 
(L11B100) after 3 weeks of storage in the fridge and under room 
temperature. EE was calculated from the BPO contents in the 
liposome dispersion before (precentrifugation sample) and after 
centrifugation (pellet and supernatant). (Mean ± SD, n = 3)  
 
After Centrifugation Batch Precentrifugation 










Storage in the fridge 
L11B12.5 11070 ± 112 7920 ±100 4230 ± 247 65 ± 1 66 ± 2 
L11B25 21543 ± 298 13895 ± 230 7798 ± 21 63.8 ± 2 65 ± 2 
L11B50 36598 ± 116 22141 ± 115 14712 ± 378 59.8 ± 3 61 ± 2 
L11B100 74621 ± 214 46496 ± 333 28952 ± 200 61 ± 1 62 ± 1 
Storage under room temperature 
L11B12.5 10120 ± 174 669 ± 45 345 ± 34 66 ± 1 66 ± 2 
L11B25 22301 ± 240 14228 ± 375 8162 ± 111 63 ± 3 64 ± 3 
L11B50 37912 ± 116 23467 ± 125 14634 ± 208 61 ± 3 62 ± 3 









In vitro drug release profile 
Figure 11 shows the in vitro BPO release profiles of liposomes prepared with PC:CH 
ratio of 1:1 and stored for 3 weeks at 4°C and room temperature, respectively. Unlike 
corresponding freshly-prepared liposomes which released only about 50% of the BPO 
load after 24 h, the stored liposomes showed a much faster BPO release rate, with 80% or 
more of the BPO load released within the first 2 h. In addition, the zero-order BPO 
release profile that characterized the freshly prepared liposomes was abolished upon 
storage. Instead, the stored liposomes exhibited an extensive burst effect, with little 
further drug released beyond 3 h. This release profile was comparable to the control BPO 
solutions, which released more than 90% of BPO load within 2 h. Again, storage 
temperature and the initial BPO loading did not seem to have significant effects on the in 







































































Figure 11.  In vitro release profiles of BPO from liposomes produced with 
different BPO concentrations and stored in the fridge (a) and under 
room temperature (b) for 3 weeks: 12.5 mg/ml (L11B12.5), 25 mg/ml 
(L11B25), 50 mg/ml (L11B50) and 100 mg/ml (L11B100). Control 
experiments were conducted with BPO solutions of different 
concentrations: 12.5 mg/ml (S0B12.5), 25 mg/ml (S0B25), 50 mg/ml 
(S0B50) and 100 mg/ml (S0B100). (Mean ± SD, n = 3). 
 
 
5.6 In  vitro antibacterial activity 
Storage did not inactivate the antibacterial activity of the BPO liposomes prepared with 
PC:CH ratio of 1:1. Zones of inhibition were observed in agar plates inoculated with P. 
acnes and incubated with the 3-week old BPO liposomal formulations (Figure 12). 
Moreover, the zones of inhibition obtained were significantly larger (p < 0.05, 2-way 
ANOVA) than equivalent freshly prepared BPO liposomal samples. This phenomenon 
was not observed for the control BPO solutions, which exhibited comparable zones of 
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inhibition before and after 3 weeks of storage (p > 0.05, 2-way ANOVA) (Figure 13). 
These results are consistent with the effects of storage on the in vitro BPO release profiles 
of the liposome and solution formulations, suggesting that the antibacterial activity of the 
BPO liposomes was dependent on the concentration of BPO released from the liposomes. 
Nevertheless, despite the increase in the zone of inhibition, the stored BPO liposomes 
continued to show weaker antibacterial activity compared to equivalent, stored BPO 
control solutions. For the stored liposomes, the zones of inhibition were below 1.5 cm, 
even at the highest BPO loading concentration of 100 mg/ml. In contrast, the zones of 
inhibitions observed for stored BPO solutions were consistently larger than 1.5 cm, even 
at a BPO concentration of 25 mg/ml. These results were inconsistent with the in vitro 
release profiles of BPO from the two formulations. Both the liposomal and solution 
formulations released >80% of their BPO load within the first 2 h, yet they exhibited 
differential antibacterial activity. This could imply that the presence of liposomal 
materials, e.g. the lipids, could hinder the antibacterial activity of the BPO. The storage 
temperature did not show an apparent influence on the antibacterial activity of the BPO 
liposomes, because comparable zones of inhibitions were obtained for liposomes stored 
at 4°C (L11B-FG) and those stored at ambient temperature (L11B-R).  
 
The bigger zone of inhibitions for the BPO solutions compared with those for the BPO 
liposomes can be explained by the differing BPO content present for the antibacterial 
studies. This is because the BPO solution formulations were simple to prepare, and BPO 
loss upon preparation would be minimal. However, this was not the case for the BPO 
liposomes, whose BPO content was about 15% less than the BPO solutions. Analysis by 
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2-way ANOVA show this difference to be significant (p < 0.05). Thus, lower BPO 

































Figure 12.  Zones of inhibition of BPO liposomes with PC: CH at mole ratio 1:1 
before storage (L11B) and after it is stored in the fridge (L11B-FG) 





























Figure 13.  Zones of inhibition of BPO solutions before storage (S0B) and after it 
is stored in the fridge (S0B-FG) and under room temperature (S0B-
R). 
 
Profuse bacterial proliferation was observed in the cups containing the empty liposomes, 
indicating that bacterial inhibition observed in the sample cups was due to the BPO. 
Although bacterial growth was also detected in cups containing liposomes with BPO 
concentration of 12.5 mg/ml, the growth was not as profuse. Nevertheless, it may be 
concluded that BPO at such low concentration was insufficient to inhibit the bacteria. 
Similarly, no zone of inhibition was detected in cups containing the lipids PC and CH 







6. Final Conclusion 
 
This project started out with the hypothesis that BPO could be successfully encapsulated 
in nano-sized liposomes that would preserve the stability and antibacterial activity of the 
drug. Results from the preliminary experiments allowed us to develop, optimize and 
characterize the BPO-loaded liposomes, using cholesterol and phosphatidylcholine in the 
ratio of 3:1 as the lipids. The pressures applied during the drying down and hydration of 
lipids affected the amount of drug loss. Other factors, such as method and duration of 
agitation, as well as the filtration process, applied to extract the drug from the liposomes 
into the mobile phase for HPLC analysis played less important roles in determining the 
final BPO content in the liposomes. More than 90% of the BPO content in the liposomes 
was found to be encapsulated within the liposomes. Upon dilution with an aqueous 
medium, sustained release of the encapsulated BPO was obtained, with less than 40% of 
the drug load released in 24 h. A longer duration of sonication produced smaller but less 
stable particles where particle aggregation occurred with high frequency. This in turn can 
affect the BPO release profile.  
 
Liposomes with higher BPO loading concentration in the range of 12.5 to 100 mg/ml 
were prepared for microbiological assay. Increasing the BPO loading concentration led to 
lower EE values of between 71 to 78%, and these liposomes were unstable upon storage 
for 3 weeks. Size distribution studies and TEM examinations showed that liposomes 
prepared with PC: CH in the mole ratio of 3: 1 were much bigger after storage for 3 
weeks in the fridge (2000 nm) and much smaller after storage under room temperatures 
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(200-300 nm). Increasing the PC:CH mole ratio to 1:1 stabilized the liposomes, and the 
changes in mean size of the liposomes after storage for 3 weeks at 4°C and ambient 
temperatures were much smaller.  Although the higher cholesterol level in the liposomes 
increased the BPO encapsulation efficiency to between 74 to 83%, these values were, 
however, lower than the EE value of >90% obtained for liposomes prepared with very 
low BPO content. The lower encapsulation rate translated to faster rate and extent of drug 
from the liposomes. Storage for a further 3 weeks increased the amount of free BPO in 
the liposomal dispersion, with the result that more than 80% of the BPO load was 
released from the liposomes within 2 h. The storage temperature of 4°C and room 
temperature, as well as the BPO loading concentration in the liposomes, had minimal 
effects on the size distribution, EE, and in vitro BPO release profile of the liposomes.  
 
BPO in the phospholipids liposome formulations had an antibacterial effect against P. 
acnes. For effective inhibition of P. acnes, BPO concentrations of 25 mg/ml and above 
had to be used to prepare the liposomal samples. Antibacterial efficacy was not affected 
by the ratio of phosphatidylcholine and cholesterol in the lipid bilayer nor the storage 
temperature. More studies have to be conducted to confirm if BPO encapsulated in 
liposomes exhibit sustained release.   
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7. Future Work 
In the present work, BPO encapsulated in liposomes have been successfully developed, 
optimized and characterized. BPO liposomes have also exhibited in-vitro antibacterial 
activity against P. acnes, the major cause of inflammation in acne. Although pure BPO 
solutions in this study were more effective in inhibiting the bacteria, future studies will 
have to be conducted to determine whether the liposomal BPO is not only effective in 
inhibiting P. acnes but also in reducing the skin irritation and itching common associated 
with a conventional BPO formulation. 
 
The next phase of work would be to optimize the formulation so that the BPO liposome 
dispersions may be developed into pharmaceutically relevant products. Additional work 
will be required to stabilize the BPO liposomes so that consistent products could be 
produced that are stable to storage, such as a gel base or a lotion so as to study the in-
vitro anti-acne properties of BPO liposomes as a therapy for patients suffering from mild 
to moderate acne vulgaris.  
 
A double-blind clinical study can be conducted to assess the safety, efficacy and 
efficiency of BPO in phospholipids liposomes vs. a commercial product and/or a 
pharmacopoeial BPO preparation. The hypothesis of the trial would be that BPO 
encapsulated in liposomes is therapeutically superior to conventional BPO in solution or 
gel formulations in the treatment of acne vulgaris. There must be an overall improvement 
in patient outcome, in the form of reduction in total number of skin lesions and local 
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Appendix 1. BPO standard curve determined by HPLC 























10 50 100 150 200 
1 0.928 1.416 0.884 0.035 0.002 
2 3.527 4.470 0.202 1.360 1.060 
3 3.464 1.318 1.650 1.190 0.383 
 
Appendix 2. Coefficient of variation for BPO liposomes analyzed over 3 days 
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